TY - JOUR
T1 - Interventional Pharmacoeconomics
T2 - A Novel Mechanism for Unlocking Value
AU - Serritella, Anthony V.
AU - Strohbehn, Garth W.
AU - Goldstein, Daniel A.
AU - Lichter, Allen S.
AU - Ratain, Mark J.
N1 - Funding Information:
G.W.S. is supported by the Richard and Debra Gonzalez Research Fellowship at the University of Chicago (established through philanthropy by Abbott Laboratories). A.S.L. serves on boards of Cellworks and LifeLink as well as clinical advisory board for Ascentage Pharmaceuticals. M.J.R. has served as a patent litigation consultant and expert witness on behalf of multiple generic pharmaceutical companies; has received consulting fees from Ascentage, Aptevo, Pneuma Respiratory, and Shionogi; clinical trial funding from AbbVie, Dicerna, and Genentech; and other support from BeiGene. All other authors declared no competing interests for this work.
Publisher Copyright:
© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Cancer care’s sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.
AB - Cancer care’s sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.
UR - http://www.scopus.com/inward/record.url?scp=85084511401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084511401&partnerID=8YFLogxK
U2 - 10.1002/cpt.1853
DO - 10.1002/cpt.1853
M3 - Review article
C2 - 32298471
AN - SCOPUS:85084511401
SN - 0009-9236
VL - 108
SP - 487
EP - 493
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 3
ER -
